Reuters logo
in 10 months
BRIEF-UCB CIMZIA Phase 3 trial meets co-primary efficacy endpoints
October 3, 2016 / 5:26 AM / in 10 months

BRIEF-UCB CIMZIA Phase 3 trial meets co-primary efficacy endpoints

1 Min Read

Oct 3 (Reuters) - UCB SA :

* CIMZIA (certolizumab pegol) Phase 3 trial meets co-primary efficacy endpoints in patients with moderate-to-severe chronic plaque psoriasis

* In CIMPASI-2 trial, CIMZIA demonstrated statistically significant improvements for both co-primary endpoints compared to placebo at both treatment doses Source text: bit.ly/2dlyXxi Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below